New study underlines benefits of adjunctive lacosamide for epilepsy

A new study has underlined the potential benefits offered by lacosamide, an antiepileptic drug (AED) therapy for the adjunctive treatment of focal-onset seizures.

Researchers from Western Infirmary in Glasgow conducted a prospective audit to assess outcomes associated with the AED in everyday clinical practice, with a total of 160 patients being treated with the drug.

It was revealed that 35 patients remained seizure-free for at least 6 months on a stable lacosamide dose, while 35 had a reduction in seizure frequency of 50 per cent or more. Additionally, a further 54 reported a marginal benefit.

Moreover, five patients became seizure-free on lacosamide monotherapy following withdrawal of their initial treatment.

The researchers concluded: “Lacosamide is a well-tolerated and effective AED for focal-onset seizures with or without secondary generalisation, regardless of concomitant treatment. Commonest dose-related side effects were neurotoxic in nature.”

Lacosamide has been approved in Europe since 2008 and is sold under the brand name Vimpat.

Posted by Anne Brown

Publication abstract:

News Updates

Sign up for Research updates

News categories